We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




Simple Blood Test Predicts Neuroendocrine Tumor Response to Radiopharmaceutical Therapy

By LabMedica International staff writers
Posted on 11 Apr 2023
Print article
Image: Blood-based biomarkers can accurately predict neuroendocrine tumor response to radiopharmaceutical therapy (Photo courtesy of Freepik)
Image: Blood-based biomarkers can accurately predict neuroendocrine tumor response to radiopharmaceutical therapy (Photo courtesy of Freepik)

Biomarkers have been employed to forecast treatment outcomes for breast, prostate, and other types of cancer, although no objective methods currently exist for predicting the success of radiopharmaceutical therapy for neuroendocrine tumors. Now, a new study has revealed that a simple blood test can supply doctors with crucial information to ascertain if peptide receptor radionuclide therapy (PRRT) is likely to be effective in patients with neuroendocrine cancer. The blood-based biomarker PPQ can accurately predict PRRT responsiveness in 96% of patients, and changes in another biomarker, NETest, correlate with PRRT response in 90% of cases.

Previously, a group of nuclear medicine physicians at Memorial Sloan Kettering Cancer Center (MSK, New York, NY, USA) had introduced the blood-based biomarkers PPQ and NETest as indicators for the success of PRRT treatment. In this new study, the team aimed to validate the significance of PPQ and NETest in predicting and monitoring PRRT response. The new study included 67 patients with somatostatin receptor-positive gastroenteropancreatic and lung neuroendocrine tumors, all of whom had metastatic disease and prior treatments. The participants submitted blood samples before each PRRT cycle and during follow-up. PPQ was scored as either positive (likely to respond) or negative (unlikely to respond), while NETest was measured on a scale of zero to 100, with 20 being the upper limit of normality.

Of the 67 patients, 40 were classified as PPQ+ and 39 of them (98%) responded to PRRT. Among the 27 PPQ- patients, 25 experienced disease progression despite PRRT. The overall predictive accuracy of PPQ was 96%. Prior to PRRT therapy, all patients exhibited elevated NETest levels. In PRRT responders, baseline NETest levels were 67, decreasing by 37% after treatment. For non-responders, baseline NETest levels were 44, which rose by 76% during follow-up. NETest's accuracy in determining PRRT response was 90%.

“The results of this study demonstrate that not all tumors are created equal; some are more prone to respond to PRRT, and some are less susceptible to radiopharmaceutical therapy,” said Lisa Bodei, MD, PhD, nuclear medicine physician at Memorial Sloan Kettering Cancer Center. “This is the reason why our research is important: to understand from the start which patients will require an intensified treatment plan and which patients, instead, can benefit from a lighter regimen will tremendously improve their management.”

Related Links:
MSK

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Unit-Dose Packaging solution
HLX
New
Respiratory Syncytial Virus Test
QuickVue RSV Test
New
DNA topoisomerase I ELISA
Anti-Scl-70 ELISA Test

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The discovery of a new blood group has solved a 50- year-old mystery (Photo courtesy of 123RF)

Newly Discovered Blood Group System to Help Identify and Treat Rare Patients

The AnWj blood group antigen, a surface marker discovered in 1972, has remained a mystery regarding its genetic origin—until now. The most common cause of being AnWj-negative is linked to hematological... Read more

Microbiology

view channel
Image: The inbiome molecular culture ID technology has received FDA breakthrough device designation (Photo courtesy of inbiome)

Revolutionary Molecular Culture ID Technology to Transform Bacterial Diagnostics

Bacterial infections pose a major threat to public health, contributing to one in five deaths worldwide. Current diagnostic methods often take several days to provide results, which can delay appropriate... Read more

Pathology

view channel
Image: Confocal- & laminar flow-based detection scheme of intact virus particles, one at a time (Photo courtesy of Paz Drori)

Breakthrough Virus Detection Technology Combines Confocal Fluorescence Microscopy with Microfluidic Laminar Flow

Current virus detection often relies on polymerase chain reaction (PCR), which, while highly accurate, can be slow, labor-intensive, and requires specialized lab equipment. Antigen-based tests provide... Read more

Industry

view channel
Image: The GeneXpert system’s fast PCR Xpert tests can fight AMR and superbugs with fast and accurate PCR in one hour (Photo courtesy of Cepheid)

Cepheid Partners with Fleming Initiative to Fight Antimicrobial Resistance

Antimicrobial resistance (AMR) is responsible for over one million deaths globally each year and poses a growing challenge in treating major infectious diseases like tuberculosis, Escherichia coli (E.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.